Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 674-679

  McSorley, Meghan A ^a   Alberg, Anthony J ^a,b   Allen, Diane S ^c   Allen, Naomi E ^d   Brinton, Louise A ^e   Dorgan, Joanne F ^f   Kaaks, Rudolf ^g   Rinaldi, Sabina ^g   Helzlsouer, Kathy J ^a,h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NATIONAL CANCER INSTITUTE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h MERCY MEDICAL CENTER   (United States)

Author keywords

Cohort study; Epidemiology; Follicle stimulating hormone (FSH); Gonadotropins; Ovarian cancer

Indexed keywords

FOLLITROPIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CIRCULATION; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE DETERMINATION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MARYLAND; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650088520     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24406     Document Type: Article

References (21)

1. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
2. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004;83:783-95.
3. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
4. Arslan AA, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Lukanova A, Afanasyeva Y, Lenner P, Krogh V, Muti P, Rinaldi S, Kaaks R, Berrino F, et al. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2003;12:1531-35.
5. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007;109:933-41.
6. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 1993;269:1123-26.
7. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-59.
8. Fortner KB, Lipari CW. Hyperandrogenism. In: Fortner KB, Szymanski LM, Fox HE, Wallach EE, eds. The Johns Hopkins manual of gynecology and obstetrics, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2007. (R2 OnLine Library. http://www.R2Library.com/ marc-frame.aspx?ResourceID5486).
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
10. Zhou B, Sun Q, Cong R Gu H, Tang N, Yang L, Wang B. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008;108:641-51.
11. Reyna R, Traynor KD, Hines G, Boots LR, Azziz R. Repeated freezing and thawing does not generally alter assay results for several commonly studied reproductive hormones. Fertil Steril 2001;76:823-25.
12. Geller S, Scholler R. FSH and LH pituitary reserve and output in the postmenopause. Maturitas 1980;2:45-52.
13. Hall JE, Lavoie HB, Marsh EE, Martin KA. Decrease in gonadotropin- releasing hormone (GnRH) pulse frequency with aging in postmenopausal women. J Clin Endocrinol Metab 2000;85:1794-800.
14. Kwekkeboom DJ, de Jong FH, van Hemert AM, Vandenbroucke JP, Valkenburg HA, Lamberts SW. Serum gonadotropins and alpha-subunit decline in aging normal postmenopausal women. J Clin Endocrinol Metab 1990;70:944-50.
15. Backer LC, Rubin CS, Marcus M, Kieszak SM, Schober SE. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). Menopause 1999;6:29-35.
16. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
17. Ivarsson K, Sundfeldt K, Brannstrom M, Hellberg P, Janson PO. Diverse effects of FSH and LH on proliferation of human ovarian surface epithelial cells. Hum Reprod 2001;16:18-23.
18. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76:80-88.
19. Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ. Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 2002;78:1096-99.
20. Ho SM, Lau KM, Mok SC, Syed V. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 2003;22:4243-56.
21. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.